Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT00894569
Other study ID # EUDRACT 2008-003174-18
Secondary ID
Status Not yet recruiting
Phase Phase 2
First received May 6, 2009
Last updated May 13, 2009
Start date July 2009
Est. completion date August 2011

Study information

Verified date May 2009
Source Heidelberg University
Contact Alwin Kraemer, Prof.
Phone +49-6221-42-1441
Email a.kraemer@dkfz.de
Is FDA regulated No
Health authority Germany: Paul-Ehrlich-Institut
Study type Interventional

Clinical Trial Summary

The purpose of this study is to determine whether an addition of cetuximab to carboplatin/paclitaxel can improve efficacy in comparison to carboplatin/paclitaxel in patients with carcinoma of unknown-primary.


Description:

Carcinomas of unknown primary (CUP) account for approximately 2-5% of all cancer diagnoses. Except for some subsets with favorable prognosis, for most of these patients, treatment options are limited, and no standard first-line regimen has been identified. Standard therapy for patients with adeno- or undifferentiated CUP is Paclitaxel/Carboplatin, yielding response rates between 20-40%. In recent years, targeted therapies with inhibitors to EGFR, several tyrosine kinases, and VEGF have been shown to improve survival in different solid tumor entities. Cetuximab, a monoclonal antibody against the EGF receptor, has proved efficacy in combination with chemotherapy in patients with metastatic colorectal cancer, gastric cancer, squamous cell carcinoma of head and neck and non-small cell lung cancer (NSCLC). Because of these promising results it seems to be reasonable to examine the impact of adding cetuximab to standard chemotherapy with paclitaxel and carboplatin in patients with CUP.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 150
Est. completion date August 2011
Est. primary completion date July 2010
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Histologic or cytologic proven, non-resectable carcinoma of unknown primary (adenocarcinoma or non-differentiated carcinoma)

- Measurable tumor lesion(s) according to RECIST criteria

- WHO PS 0 to 1

- Paclitaxel/Carboplatin with or without Cetuximab in Adeno- and Undifferentiated CUP (PACET-CUP)

- Signed written informed consent

- = 18 years of age

- Effective contraception for both male and female subjects if the risk of conception exists

- Adequate bone marrow function:

- Neutrophiles blood cell count (NBC) = 1,5x109/L

- Platelet count = 100x109/L

- Hemoglobin = 5,00 mmol/L (8 g/dL)

- Adequate liver and renal function:

- Bilirubin = 1,5 x upper normal level (UNL) and not increasing more than 25% within the last 4 weeks

- ASAT and ALAT = 2,5 x UNL or in case of liver metastases = 5 x UNL

- Serum creatinine = 1.5 x UNL

Exclusion Criteria:

- Previous exposure to epidermal growth factor receptor-targeting therapy

- Previous chemotherapy except adjuvant treatment with progression of disease documented > 6 months after end of adjuvant treatment

- Radiotherapy or major abdominal or thoracic surgery within the last 4 weeks before inclusion

- Concurrent chronic systemic immunotherapy, chemotherapy or hormone therapy

- Investigational agents or participation in clinical trials within 30 days before treatment start in this study

- Clinically relevant coronary disease or myocardial infarction within 12 months before study entry

- Possibility of a curative local treatment (surgery and/or radiotherapy)

- Women with axillary node metastasis as predominant tumor site

- Women with peritoneal carcinomatosis as predominant tumor site

- Men < 50 years old with retroperitoneal or mediastinal lymph node +/- lung metastases as predominant tumor site

- Identification of the primary or suspicion of a specific tumor entity by reference histopathology (i.e., Her-2 positive or hormone receptor positive tumors corresponding to breast cancer, CK7-negative/CK20- positive tumors with high probability for colorectal cancer)

- Peripheral neuropathy > CTC grade I

- Previous malignancy within the last 5 years (except history of basal cell carcinoma of skin or pre-invasive carcinoma of the cervix with adequate treatment)

- History of severe psychiatric illness

- Life expectancy less than six weeks

- Drug or alcohol abuse

- Known hypersensitivity reaction to any of the components of the study treatment

- Pregnancy (absence to be confirmed by ß-hCG test) or lactation period

- Brain metastasis and/or leptomeningeal disease (known or suspected)

- Acute or sub-acute intestinal occlusion or inflammatory bowel disease

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
paclitaxel/carboplatin
6 cycles paclitaxel 175 mg/m² and carboplatin AUC 5, repetition d22.
cetuximab
cetuximab (400 mg/m² first dose, 250 mg/m² weekly) until disease progression

Locations

Country Name City State
Germany University Hospital Heidelberg, Med. Dep. v Heidelberg

Sponsors (2)

Lead Sponsor Collaborator
Heidelberg University Merck KGaA

Country where clinical trial is conducted

Germany, 

Outcome

Type Measure Description Time frame Safety issue
Primary The rate of progression free survival at 8 months after randomization, defined as the proportion of patients alive with stable disease, partial or complete response, according to RECIST is the primary endpoint for the final analysis. 8 months after randomization No
Secondary Efficacy: Response rate, Median progression free survival (PFS), Overall survival (OS) Toxicity until end of study Yes
See also
  Status Clinical Trial Phase
Recruiting NCT05283226 - Study to Evaluate the Safety and Efficacy of Oral NRC-2694-A in Combination With Paclitaxel in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma, Who Progressed on or After Immune Checkpoint Inhibitor Therapy Phase 2
Active, not recruiting NCT04362072 - Study of Lorlatinib In People With ALK-positive Non-small Cell Lung Cancer Phase 4
Completed NCT04033991 - Study of Patients With Metastatic and/or Advanced Renal Cell Carcinoma, Treated With Sunitinib/Axitinib.
Recruiting NCT02292641 - Beyond TME Origins N/A
Not yet recruiting NCT02907606 - Urinary Circulating Tumor DNA Detection in Non-small Cell Lung Cancer: a Prospective Study N/A
Completed NCT02507544 - A Safety and Pharmacokinetic Study of TRX-818 Administered Orally to Patients With Advanced Cancer Phase 1
Completed NCT01942200 - A Non Interventional Study With Oxaliplatin Onkovis (Oxaliplatin) Utilized for the Treatment of Cancer
Completed NCT01061645 - Study of MOC31-PE in Antigen Positive Carcinomas Phase 1
Completed NCT00532155 - A Study of Aflibercept Versus Placebo in Patients With Second-Line Docetaxel for Locally Advanced or Metastatic Non-Small-Cell Lung Cancer Phase 3
Terminated NCT00557596 - A Phase 1-2, XIAP Antisense AEG35156 With Gemcitabine in Patients With Advanced Pancreatic Cancer Phase 1/Phase 2
Completed NCT00216372 - Efficacy and Safety of Lanreotide Microparticles as Palliative Treatment in Peritoneal Carcinomatosis Phase 3
Recruiting NCT06022757 - Study of XNW5004 Tablet in Combination With KEYTRUDA® (Pembrolizumab) in Subjects With Advanced Solid Tumors Who Failed Standard Treatments (KEYNOTE F19) Phase 1/Phase 2
Recruiting NCT05520281 - Short-term Psychodynamic Psychotherapy in Serious Physical Illness N/A
Recruiting NCT05752357 - The Role of Pre-operative and Post-operative Circulating Tumor Cells in Gastric Cancer.
Not yet recruiting NCT05023928 - Tumor Antigen-sensitized DC Vaccine as an Adjuvant Therapy for Esophagus Cancer Phase 1
Completed NCT00446446 - PRISM (Panitumumab Regimen In Second-line Monotherapy of Head and Neck Cancer) Phase 2
Recruiting NCT04566952 - Anlotinib Combined With Dose-reduced Olaparib in Patients With Platinum-Sensitive Recurrent Ovarian Cancer Phase 2
Not yet recruiting NCT06112041 - The Prospective Clinical Study of Precision PRaG Therapy in Elderly Patients With Advanced Solid Malignant Tumors (PRaG9.0) Phase 2
Completed NCT03562897 - Evaluation of Ocoxin-Viusid® in Advanced or Metastatic Ovarian Epithelial Cancer Phase 2
Recruiting NCT06013111 - An Exploratory Clinical Study Evaluating the Safety and Efficacy of Anti-CEA-CAR-T Cells Injection in Patients With CEA+ Locally Advanced and/or Metastatic Solid Tumors Phase 1